» Articles » PMID: 16172309

Incidence of Cancer Among Patients with Atopic Dermatitis

Overview
Journal Arch Dermatol
Specialty Dermatology
Date 2005 Sep 21
PMID 16172309
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the risk of skin cancer and other cancers among patients with atopic dermatitis.

Design: Register-based retrospective cohort study.

Setting: Sweden. Patients A total of 15 666 hospitalized patients identified in the national Inpatient Register as having discharge diagnoses of atopic dermatitis between January 1, 1965, and December 31, 1999. Interventions The National Swedish Cancer Register coded malignant neoplasms during the entire period of study. Follow-up time was calculated from the date of entry in the cohort until the occurrence of a first cancer diagnosis, emigration, death, or the end of the observation period, whichever occurred first.

Main Outcome Measures: Follow-up by means of record linkages to several nationwide registers, among them the National Swedish Cancer Register. Standardized incidence ratios (SIRs) (the ratios of numbers of observed patients with cancer to expected numbers of incident cases of cancer) estimated the risk of developing cancer relative to the risks in the age-, sex-, and calendar year- matched general Swedish population.

Results: After excluding the first year of follow-up, the risk of developing any cancer was increased by 13% (95% confidence interval [CI] of SIR, 1.01-1.25, based on 311 observed patients with cancer). Excess risks were observed for cancers of the esophagus (SIR, 3.5; 95% CI, 1.3-7.7; 6 patients), pancreas (SIR, 1.9; 95% CI, 1.0-3.4; 11 patients), brain (SIR, 1.6; 95% CI, 1.1-2.4; 27 patients), and lung (SIR, 2.0; 95% CI, 1.3-2.8; 31 patients) and for lymphoma (SIR, 2.0; 95% CI, 1.4-2.9; 29 patients). There was a nonsignificant 50% excess risk for nonmelanoma skin cancer (SIR, 1.5; 95% CI, 0.8-2.6; 12 patients), seemingly confined to men and to the first 10 years of follow-up. Malignant melanoma did not occur more often than expected.

Conclusions: The observed risk elevations, all of borderline statistical significance, should be interpreted cautiously. We could not control for possible confounding by cases of cancer caused by smoking, and the combination of multiple significance testing and few observed patients may have generated chance findings.

Citing Articles

The causal effect of atopic dermatitis on lung cancer: A Mendelian randomization study.

Huang P, Wen F, Wu Q, Zhang P, Li Q Skin Res Technol. 2024; 30(7):e13841.

PMID: 38965791 PMC: 11224128. DOI: 10.1111/srt.13841.


Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.

Simpson E, Silverberg J, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister K Am J Clin Dermatol. 2024; 25(4):639-654.

PMID: 38888681 PMC: 11193687. DOI: 10.1007/s40257-024-00869-w.


Cracking the code: unveiling the nexus between atopic dermatitis and addictive behavior: a cross-sectional exploration of risk factors.

Mick A, Wecker H, Ziehfreund S, Maul J, Biedermann T, Zink A Arch Dermatol Res. 2024; 316(4):102.

PMID: 38485839 PMC: 10940371. DOI: 10.1007/s00403-024-02841-4.


Association between Atopic Dermatitis and Colorectal Cancer: TET2 as a Shared Gene Signature and Prognostic Biomarker.

Zhan Z, Huang Z, Zeng R, Luo Y, Xie Z, Chen Y J Cancer. 2024; 15(5):1414-1428.

PMID: 38356721 PMC: 10861813. DOI: 10.7150/jca.92238.


Large-scale epidemiological analysis of common skin diseases to identify shared and unique comorbidities and demographic factors.

Li Q, Patrick M, Sreeskandarajan S, Kang J, Kahlenberg J, Gudjonsson J Front Immunol. 2024; 14:1309549.

PMID: 38259463 PMC: 10800546. DOI: 10.3389/fimmu.2023.1309549.